Additional file 1 of Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non–small cell lung cancer: a modelling approach
Creators: name: Hui, Wen
name: Song, Ruomeng
name: Tao, Hongyu
name: Gao, Zhixiang
name: Zhu, Min
name: Zhang, Mingyue
name: Wu, Huazhang
name: Gong, Daichen
name: Zhang, Xiyan
name: Cai, Yuanyi
Publisher: name: figshare
Year: 2023
Subjects: Medicine
Pharmacology
Biotechnology
Mathematical Sciences not elsewhere classified
Cancer
Science Policy
Computational Biology

description: Additional file 1: Table S1. AIC and BIC of OS curve and PFS curve in the atezolizumab plus chemotherapy arm in the IMpower 130 trial. Table S2. Treatment regimens in 16 clinical trials. Table S3. Treatment regimens used in the partitioned survival model. Table S4. Serious adverse event cost and disutility for patients in China. Table S5. Serious adverse event incidence, cost and disutility of sint-chemo. Table S6. Serious adverse event incidence, cost and disutility of pem-chemo. Table S7. Serious adverse event incidence, cost and disutility of nivo-ipi-chemo. Table S8. Serious adverse event incidence, cost and disutility of tisle-chemo. Table S9. Serious adverse event incidence, cost and disutility of camre-chemo. Table S10. Serious adverse event incidence, cost and disutility of atezo-beva-chemo. Table S11. Serious adverse event incidence, cost and disutility of durva-treme-chemo. Table S12. Serious adverse event incidence, cost and disutility of atezo-chemo. Table S13. Serious adverse event incidence, cost and disutility of durva-treme. Table S14. Serious adverse event incidence, cost and disutility of chemo. Figure S1. Visual inspection of nine distributions for OS curve in the atezolizumab plus chemotherapy arm. Figure S2. Visual inspection of exponential, and loglogistic distributions for OS curve in the atezolizumab plus chemotherapy arm. Figure S3. Visual inspection of nine distributions for PFS curve in the atezolizumab plus chemotherapy arm. Figure S4. Visual inspection of genf, and loglogistic distributions for PFS curve in the atezolizumab plus chemotherapy arm. Figure S5. Deterministic sensitivity analysis of sint-chemo versus chemo. FigureS6. Deterministic sensitivity analysis of pem-chemo versus chemo. Figure S7. Deterministic sensitivity analysis of nivo-ipi-chemo versus chemo. Figure S8. Deterministic sensitivity analysis of tisle -chemo versus chemo. Figure S9. Deterministic sensitivity analysis of camre-chemo versus chemo. Figure S10. Deterministic sensitivity analysis of nivo-ipi versus chemo. Figure S11. Deterministic sensitivity analysis of atezo-beva-chemo versus chemo. Figure S12. Deterministic sensitivity analysis of durva-treme-chemo versus chemo. Figure S13. Deterministic sensitivity analysis of atezo-chemo versus chemo. Figure S14. Deterministic sensitivity analysis of durva-treme versus chemo. Figure S15. Probabilistic sensitivity analysis of sint-chemo versus chemo. Figure S16. Probabilistic sensitivity analysis of pem-chemo versus chemo. Figure S17. Probabilistic sensitivity analysis of nivo-ipi-chemo versus chemo. Figure S18. Probabilistic sensitivity analysis of tisle-chemo versus chemo. Figure S19. Probabilistic sensitivity analysis of camre-chemo versus chemo. Figure S20. Probabilistic sensitivity analysis of nivo-ipi versus chemo. Figure S21. Probabilistic sensitivity analysis of atezo-beva-chemo versus chemo. Figure S22. Probabilistic sensitivity analysis of durva-treme-chemo versus chemo. Figure S23. Probabilistic sensitivity analysis of atezo-chemo versus chemo. Figure S24. Probabilistic sensitivity analysis of durva-treme versus chemo.